{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pseudomonas+Infections&page=2",
    "query": {
      "condition": "Pseudomonas Infections",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pseudomonas+Infections&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:15:27.771Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02421120",
      "title": "Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Cystic Fibrosis Pulmonary Exacerbation",
        "Pseudomonas Aeruginosa Infection"
      ],
      "interventions": [
        {
          "name": "Ceftolozane/Tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph L. Kuti, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-09",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 4,
      "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02421120"
    },
    {
      "nct_id": "NCT06016088",
      "title": "A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis Lung",
        "Respiratory Infections, Recurrent, Chronic",
        "Pseudomonas Aeruginosa"
      ],
      "interventions": [
        {
          "name": "RSP-1502",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin inhalation solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Respirion Pharmaceuticals Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2024-04-01",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Northfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06016088"
    },
    {
      "nct_id": "NCT02015663",
      "title": "Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Tobramycin Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Sacramento, California + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015663"
    },
    {
      "nct_id": "NCT01319253",
      "title": "A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Pseudomonas Aeruginosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2011-03",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-06",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01319253"
    },
    {
      "nct_id": "NCT01404234",
      "title": "Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Pseudomonas Aeruginosa"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "Up to 12 Years"
      },
      "enrollment_count": 61,
      "start_date": "2011-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-05-29",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404234"
    },
    {
      "nct_id": "NCT01570192",
      "title": "Clinical Trials to Reduce the Risk of Antimicrobial Resistance",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "IV meropenem",
          "type": "DRUG"
        },
        {
          "name": "I.V. Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h",
          "type": "DRUG"
        },
        {
          "name": "Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.",
          "type": "DRUG"
        },
        {
          "name": "tobramycin nebulization",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 8,
      "location_summary": "San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "North Liberty",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570192"
    },
    {
      "nct_id": "NCT02054156",
      "title": "OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "azithromycin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin solution for inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bonnie Ramsey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 221,
      "start_date": "2014-06",
      "completion_date": "2018-08-23",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 45,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02054156"
    },
    {
      "nct_id": "NCT01641822",
      "title": "Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match AZLI",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin inhalation solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2012-12",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 71,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01641822"
    },
    {
      "nct_id": "NCT06159725",
      "title": "A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Persistent Infection",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "CMTX-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clarametyx Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2024-06-24",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Franciso",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06159725"
    },
    {
      "nct_id": "NCT00097773",
      "title": "Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tobramycin solution for inhalation (TOBI)",
          "type": "DRUG"
        },
        {
          "name": "Oral placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral ciprofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Year to 12 Years"
      },
      "enrollment_count": 304,
      "start_date": "2004-09",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-05-22T08:15:27.771Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097773"
    }
  ]
}